This website is for UK Healthcare Professionals only

This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of psoriasis and psoriatic arthritis. SKYRIZI® (risankizumab) and adalimumab prescribing information & adverse event reporting information can be found below.

Expert Perspectives

Getting It Right First Time – GIRFT and Sequencing

Hear from Dr Keith Wu as he uses real-world data and case studies in a presentation that addresses the key concepts of biological sequencing in psoriasis management, the potential costs of biologic failure, and the importance of ‘getting it right first time’ both for patients and for the NHS.

Getting It Right First Time – GIRFT and Sequencing

Hear from Dr Keith Wu as he uses real-world data and case studies in a presentation that addresses the key concepts of biological sequencing in psoriasis management, the potential costs of biologic failure, and the importance of ‘getting it right first time’ both for patients and for the NHS.

UK-RISN-240635. Date of preparation February 2025.

References

  1. Reich K, et al. Lancet 2019; 394: 576-586.
  2. Gordon KB, et al. Lancet 2018; 392: 650-661.
  3. Warren RB, et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
  4. SKYRIZI: Summary of Product Characteristics.

UK-RISN-240591. Date of preparation: March 2025.